Antag Therapeutics secured DKK 24 million from Broadview Ventures et all

Antag Therapeutics, a Copenhagen, Denmark-based preclinical stage biotechnology company focused on developing therapies for dietary-related metabolic diseases, announced the completion of a DKK 24M ($3.6M) capital investment round.

The money was provided by a range of investors including Broadview Ventures (US), Novo Seeds (DK) and VF Venture (DK).

Antag Therapeutics, led by chairman Kirsten Drejer and CEO Alexander Sparre-Ulrich, is a spinout from the University of Copenhagen and stems from the research groups of Professors Mette M. Rosenkilde and Jens J. Holst. The company focuses on developing therapies for dietary-related metabolic diseases and its current lead therapy is a glucose-dependent insulinotropic peptide receptor (GIPR) antagonist for inducing weight loss in obese patients with Type-2 Diabetes.